Morgan Stanley’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-160,283
| Closed | -$3.91M | – | 6849 |
|
|
2017
Q4 | $3.91M | Buy |
160,283
+143,941
| +881% | +$2.77M | ﹤0.01% | 3364 |
|
|
2017
Q3 | $302K | Buy |
16,342
+4,276
| +35% | +$74.1K | ﹤0.01% | 5155 |
|
|
2017
Q2 | $200K | Buy |
12,066
+999
| +9% | +$13.9K | ﹤0.01% | 5329 |
|
|
2017
Q1 | $153K | Sell |
11,067
-10,899
| -50% | -$175K | ﹤0.01% | 5437 |
|
|
2016
Q4 | $417K | Buy |
21,966
+20,448
| +1,347% | +$392K | ﹤0.01% | 5036 |
|
|
2016
Q3 | $33K | Buy |
1,518
+1,368
| +912% | +$25.7K | ﹤0.01% | 5755 |
|
|
2016
Q2 | $3K | Sell |
150
-2,181
| -94% | -$37.6K | ﹤0.01% | 6334 |
|
|
2016
Q1 | $43K | Buy |
2,331
+358
| +18% | +$5.79K | ﹤0.01% | 5677 |
|
|
2015
Q4 | $33K | Sell |
1,973
-475
| -19% | -$8.07K | ﹤0.01% | 5874 |
|
|
2015
Q3 | $44K | Sell |
2,448
-198
| -7% | -$4.41K | ﹤0.01% | 5787 |
|
|
2015
Q2 | $69K | Sell |
2,646
-16,818
| -86% | -$425K | ﹤0.01% | 5752 |
|
|
2015
Q1 | $427K | Buy |
+19,464
| New | +$420K | ﹤0.01% | 4769 |
|
Morgan Stanley's ENTL Position: Q1 2018 in Review
Morgan Stanley sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 160,283 shares — an estimated $3.91M sold.
Morgan Stanley first reported a position in ENTL in Q1 2015 and held it in 12 quarters. The position peaked at $3.91M in Q4 2017. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.
- Morgan Stanley reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
- Morgan Stanley sold 160,283 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $3.91M.
- Morgan Stanley first reported a position in Entellus Medical, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
- Morgan Stanley's Entellus Medical, Inc. Common Stock position peaked at $3.91M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.
Based on Morgan Stanley's 13F filing for Q1 2018, filed 14 May 2018.